| Literature DB >> 33858178 |
Zain I Sharif1, Vincent Galand2,1, William J Hucker1, Jagmeet P Singh1.
Abstract
Symptomatic heart failure (HF) patients despite optimal medical therapy and advances such as invasive hemodynamic monitoring remain challenging to manage. While cardiac resynchronization therapy remains a highly effective therapy for a subset of HF patients with wide QRS, a majority of symptomatic HF patients are poor candidates for such. Recently, cardiac contractility modulation, neuromodulation based on carotid baroreceptor stimulation, and phrenic nerve stimulation have been approved by the US Food and Drug Administration and are emerging as therapeutic options for symptomatic HF patients. This state-of-the-art review examines the role of these evolving electrical therapies in advanced HF.Entities:
Keywords: disease management; heart failure; humans; myocardial contraction; pressoreceptors
Year: 2021 PMID: 33858178 DOI: 10.1161/CIRCEP.120.009668
Source DB: PubMed Journal: Circ Arrhythm Electrophysiol ISSN: 1941-3084